Functional analysis of novel genetic variation in the thyroid hormone activating type 2 deiodinase

Journal of Clinical Endocrinology and Metabolism

Volumn 99, Issue 11, 2014, Pages E2429-E2436

  Zevenbergen, Chantal ^a   Klootwijk, Wim ^a   Peeters, Robin P ^a   Medici, Marco ^a   De Rijke, Yolanda B ^a   Huisman, Sylvia A ^b   Goeman, Henk ^c   Boot, Erik ^c   De Kuijper, Gerda ^d   De Waal, K Herman ^e   Meima, Marcel E ^a   Larsen, P Reed ^f   Visser, Theo J ^a   Visser, W Edward ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b Prinsenstichting   (Netherlands)

^c Ipse de Bruggen Center for Intellectual Disability   (Netherlands)

^d Vanboeijenoord   (Netherlands)

^e Heeren Loo Groot Schuilenburg   (Netherlands)

^f BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ENZYME; THYROID HORMONE; TYPE 2 DEIODINASE; UNCLASSIFIED DRUG; IODIDE PEROXIDASE; IODOTHYRONINE DEIODINASE TYPE II;

ANIMAL CELL; ARTICLE; CELL METABOLISM; COHORT ANALYSIS; CONTROLLED STUDY; ENZYME ACTIVITY; GENE MUTATION; GENE SEGREGATION; GENE SEQUENCE; GENETIC TRANSFECTION; GENETIC VARIABILITY; HETEROZYGOSITY; HORMONAL REGULATION; HUMAN; IN VITRO STUDY; INTELLECTUAL IMPAIRMENT; MAJOR CLINICAL STUDY; NONHUMAN; PATIENT SELECTION; PRIORITY JOURNAL; SEQUENCE ANALYSIS; THYROID HORMONE BLOOD LEVEL; BLOOD; GENETICS; MUTATION; SINGLE NUCLEOTIDE POLYMORPHISM;

HUMANS; INTELLECTUAL DISABILITY; IODIDE PEROXIDASE; MUTATION; POLYMORPHISM, SINGLE NUCLEOTIDE; THYROID HORMONES;

EID: 84910019797     PISSN: 0021972X     EISSN: 19457197     Source Type: Journal    
DOI: 10.1210/jc.2014-2281     Document Type: Article

References (44)

1. Bianco AC, Kim BW. Deiodinases: implications of the local control of thyroid hormone action. J Clin Invest. 2006; 116: 2571-2579.
2. Friesema EC, Grueters A, Biebermann H, et al. Association between mutations in a thyroid hormone transporter and severe X-linked psychomotor retardation. Lancet. 2004; 364: 1435-1437.
3. Dumitrescu AM, Liao XH, Best TB, Brockmann K, Refetoff S. A novel syndrome combining thyroid and neurological abnormalities is associated with mutations in a monocarboxylate transporter gene. Am J Hum Genet. 2004; 74: 168-175.
4. Bochukova E, Schoenmakers N, Agostini M, et al.Amutation in the thyroid hormone receptorα gene. N Engl J Med. 2012; 366: 243-249.
5. vanMullemA, van Heerebeek R, Chrysis D, et al. Clinical phenotype and mutant TRα1. N Engl J Med. 2012; 366: 1451-1453.
6. van Mullem AA, Chrysis D, Eythimiadou A, et al. Clinical phenotype of a new type of thyroid hormone resistance caused by a mutation of the TRα1 receptor: consequences of LT4 treatment. J Clin Endocrinol Metab. 2013; 98: 3029-3038.
7. Moran C, Schoenmakers N, Agostini M, et al. An adult female with resistance to thyroid hormone mediated by defective thyroid hormone receptorα. J Clin Endocrinol Metab. 2013; 98 (11): 4254-4261.
8. Crantz FR, Silva JE, Larsen PR. An analysis of the sources and quantity of 3, 5, 3′-triiodothyronine specifically bound to nuclear receptors in rat cerebral cortex and cerebellum. Endocrinology. 1982; 110: 367-375.
9. Bianco AC, Salvatore D, Gereben B, Berry MJ, Larsen PR. Biochemistry, cellular and molecular biology, and physiological roles of the iodothyronine selenodeiodinases. Endocr Rev. 2002; 23: 38-89.
10. Panicker V, Saravanan P, Vaidya B, et al. Common variation in the DIO2 gene predicts baseline psychological well-being and response to combination thyroxine plus triiodothyronine therapy in hypothyroid patients. J Clin Endocrinol Metab. 2009; 94: 1623-1629.
11. Saravanan P, Chau WF, Roberts N, Vedhara K, Greenwood R, DayanCM.Psychological well-being in patients on 'adequate' doses of l-thyroxine: results of a large, controlled community-based questionnaire study. Clin Endocrinol (Oxf). 2002; 57: 577-585.
12. He B, Li J, Wang G, et al. Association of genetic polymorphisms in the type II deiodinase gene with bipolar disorder in a subset of Chinese population. Prog Neuropsychopharmacol Biol Psychiatry. 2009; 33: 986-990.
13. Visser WE, de Rijke YB, van Toor H, Visser TJ. Thyroid status in a large cohort of patients with mental retardation: the TOP-R (Thyroid Origin of Psychomotor Retardation) study. Clin Endocrinol (Oxf). 2011; 75: 395-401.
14. Visser WE, Vrijmoeth P, Visser FE, Arts WF, van Toor H, Visser TJ. Identification, functional analysis, prevalence and treatment of monocarboxylate transporter 8 (MCT8) mutations in a cohort of adult patients with mental retardation. Clin Endocrinol (Oxf). 2013; 78: 310-315.
15. Dumitrescu AM, Liao XH, Abdullah MS, et al. Mutations in SECISBP2 result in abnormal thyroid hormone metabolism. Nat Genet. 2005; 37: 1247-1252.
16. Galton VA, Wood ET, St Germain EA, et al. Thyroid hormone homeostasis and action in the type 2 deiodinase-deficient rodent brain during development. Endocrinology. 2007; 148: 3080-3088.
17. St Germain DL, Galton VA, Hernandez A. Minireview: defining the roles of the iodothyronine deiodinases: current concepts and challenges. Endocrinology. 2009; 150: 1097-1107.
18. Adzhubei IA, Schmidt S, Peshkin L, et al. A method and server for predicting damaging missense mutations. Nat Methods. 2010; 7: 248-249.
19. Buettner C, Harney JW, Larsen PR. The 3′-untranslated region of human type 2 iodothyronine deiodinase mRNA contains a functional selenocysteine insertion sequence element. J BiolChem. 1998; 273: 33374-33378.
20. Friesema EC, Kuiper GG, Jansen J, Visser TJ, Kester MH. Thyroid hormone transport by the human monocarboxylate transporter 8 and its rate-limiting role in intracellular metabolism. Mol Endocrinol. 2006; 20: 2761-2772.
21. Bradford MM. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of proteindye binding. Anal Biochem. 1976; 72: 248-254.
22. Mol JA, Visser TJ. Synthesis and some properties of sulfate esters and sulfamates of iodothyronines. Endocrinology. 1985; 117: 1-7.
23. Gossen M, Bujard H. Tight control of gene expression in mammalian cells by tetracycline-responsive promoters. Proc Natl Acad Sci USA. 1992; 89: 5547-5551.
24. 1000 Genomes Project Consortium, Abecasis GR, Altshuler D, et al. A map of human genome variation from population-scale sequencing. Nature 2010; 467: 1061-1073.
25. National Heart, Lung, and Blood Institute. Exome Variant Server, NHLBI GO Exome Sequencing Project (ESP), Seattle, WA. http: // evs.gs.washington.edu/EVS/. Accessed April 2014.
26. Chenna R, Sugawara H, Koike T, et al. Multiple sequence alignment with the Clustal series of programs. Nucleic Acids Res. 2003; 31: 3497-3500.
27. Dentice M, Bandyopadhyay A, Gereben B, et al. The Hedgehoginducible ubiquitin ligase subunit WSB-1 modulates thyroid hormone activation and PTHrP secretion in the developing growth plate. Nat Cell Biol. 2005; 7: 698-705.
28. Gereben B, ZavackiAM, Ribich S, et al. Cellular and molecular basis of deiodinase-regulated thyroid hormone signaling. Endocr Rev. 2008; 29: 898-938.
29. Bianco AC. Minireview: cracking the metabolic code for thyroid hormone signaling. Endocrinology. 2011; 152: 3306-3311.
30. Hall JA, Ribich S, Christoffolete MA, et al. Absence of thyroid hormone activation during development underlies a permanent defect in adaptive thermogenesis. Endocrinology. 2010; 151: 4573-4582.
31. Morte B, Ceballos A, Diez D, et al. Thyroid hormone-regulated mouse cerebral cortex genes are differentially dependent on the source of the hormone: a study in monocarboxylate transporter-8- and deiodinase-2-deficient mice. Endocrinology. 2010; 151: 2381-2387.
32. Hernandez A, Quignodon L, Martinez ME, Flamant F, St Germain DL. Type 3 deiodinase deficiency causes spatial and temporal alterations in brain T3 signaling that are dissociated from serum thyroid hormone levels. Endocrinology. 2010; 151: 5550-5558.
33. Hernandez A, Morte B, Belinchon MM, Ceballos A, Bernal J. Critical role of types 2 and 3 deiodinases in the negative regulation of gene expression by T (3) in the mouse cerebral cortex. Endocrinology. 2012; 153: 2919-2928.
34. de Jong FJ, Peeters RP, den Heijer T, et al. The association of polymorphisms in the type 1 and 2 deiodinase genes with circulating thyroid hormone parameters and atrophy of the medial temporal lobe. J Clin Endocrinol Metab. 2007; 92: 636-640.
35. Panicker V, Cluett C, Shields B, et al. A common variation in deiodinase 1 gene DIO1 is associated with the relative levels of free thyroxine and triiodothyronine. J Clin Endocrinol Metab. 2008; 93: 3075-3081.
36. Appelhof BC, Peeters RP, Wiersinga WM, et al. Polymorphisms in type 2 deiodinase are not associated with well-being, neurocognitive functioning, and preference for combined thyroxine/3, 5, 3′-triiodothyronine therapy. J Clin Endocrinol Metab. 2005; 90: 6296-6299.
37. Peeters RP, van den Beld AW, Attalki H, et al.Anew polymorphism in the type II deiodinase gene is associated with circulating thyroid hormone parameters. Am J Physiol Endocrinol Metab. 2005; 289: E75-E81.
38. Canani LH, Capp C, Dora JM, et al. The type 2 deiodinase A/G (Thr92Ala) polymorphism is associated with decreased enzyme velocity and increased insulin resistance in patients with type 2 diabetes mellitus. J Clin Endocrinol Metab. 2005; 90: 3472-3478.
39. Peeters RP, van Toor H, Klootwijk W, et al. Polymorphisms in thyroid hormone pathway genes are associated with plasma TSH and iodothyronine levels in healthy subjects. J Clin Endocrinol Metab. 2003; 88: 2880-2888.
40. Gumieniak O, Perlstein TS, Williams JS, et al. Ala92 type 2 deiodinase allele increases risk for the development of hypertension. Hypertension. 2007; 49: 461-466.
41. Mentuccia D, Thomas MJ, Coppotelli G, et al. The Thr92Ala deiodinase type 2 (DIO2) variant is not associated with type 2 diabetes or indices of insulin resistance in the old order of Amish. Thyroid. 2005; 15: 1223-1227.
42. Gereben B, Goncalves C, Harney JW, Larsen PR, Bianco AC. Selective proteolysis of human type 2 deiodinase: a novel ubiquitinproteasomal mediated mechanism for regulation of hormone activation. Mol Endocrinol. 2000; 14: 1697-1708.
43. Arrojo EDR, Bianco AC. Type 2 deiodinase at the crossroads of thyroid hormone action. Int J Biochem Cell Biol. 2011; 43: 1432-1441.
44. Steinsapir J, Bianco AC, Buettner C, Harney J, Larsen PR. Substrateinduced down-regulation of human type 2 deiodinase (hD2) is mediated through proteasomal degradation and requires interaction with the enzyme's active center. Endocrinology. 2000; 141: 1127-1135.